Related Experiment Video
Updated: Jun 5, 2026
Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
Published on: April 29, 2014
Renal cell carcinoma: focus on safety and efficacy of temsirolimus
Julien Hadoux1, Stephane Vignot, Thibault De La Motte Rouge
1Service de Radiothérapie, Groupe Hospitalier Pitié Salpétrière, 47-83, boulevard de l'Hôpital, 75651 Paris Cedex 13, France.
Abstract:
Metastatic renal cell carcinoma has harboured a poor prognosis for decades with immunotherapy being the only available therapy with high toxicity and modest effect. Dependance of renal cell carcinoma oncogenesis on the mTOR pathway has led to clinical development of temsirolimus in this setting. This sirolimus derivative has shown clinical efficacy in monotherapy for poor-risk renal cell carcinoma leading to an overall survival of 10.8 months in the pivotal phase III trial of this agent. Its specific adverse events consist of metabolic dysregulation (hyperlipemia, hyperglycemia), mucositis, rash and pneumonitis which can be severe and need careful monitoring and management. In this review, we will discuss of the clinical development of this molecule, its efficacy, its safety profile and future perspectives.
Insights
Temsirolimus offers a new treatment option for metastatic renal cell carcinoma, improving survival in poor-risk patients. Careful monitoring is essential due to potential severe side effects like metabolic issues and pneumonitis.
Area of Science:
- Oncology
- Pharmacology
Background:
- Metastatic renal cell carcinoma (mRCC) historically has a poor prognosis.
- Immunotherapy offers limited efficacy and high toxicity for mRCC.
- Renal cell carcinoma (RCC) oncogenesis is linked to the mTOR pathway.
Purpose of the Study:
- To review the clinical development of temsirolimus for mRCC.
- To discuss the efficacy and safety profile of temsirolimus.
- To explore future perspectives for temsirolimus in mRCC treatment.
Main Methods:
- Review of clinical trials and literature on temsirolimus in mRCC.
- Analysis of efficacy data, including overall survival (OS).
- Assessment of the safety profile and adverse events associated with temsirolimus.
Main Results:
- Temsirolimus, a sirolimus derivative, demonstrated clinical efficacy in monotherapy for poor-risk mRCC.
- The pivotal phase III trial showed an overall survival of 10.8 months with temsirolimus.
- Key adverse events include metabolic dysregulation (hyperlipemia, hyperglycemia), mucositis, rash, and pneumonitis.
Conclusions:
- Temsirolimus provides a viable therapeutic option for mRCC, particularly in poor-risk populations.
- Management of temsirolimus requires careful monitoring for severe adverse events.
- Further research and clinical development are warranted for temsirolimus in RCC.
More Related Videos
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
